title: TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
abstract: Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3- translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo-insufficiency also did not compromise, in the 83% with genomically defined low-risk myeloma, survival or event-free survival. FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent.
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
authors.forename: John D
authors.initials: JD
authors.lastname: Shaughnessy
authors.forename: Yiming
authors.initials: Y
authors.lastname: Zhou
authors.forename: Jeff
authors.initials: J
authors.lastname: Haessler
authors.forename: Frits
authors.initials: F
authors.lastname: van Rhee
authors.forename: Elias
authors.initials: E
authors.lastname: Anaissie
authors.forename: Bijay
authors.initials: B
authors.lastname: Nair
authors.forename: Sarah
authors.initials: S
authors.lastname: Waheed
authors.forename: Yazan
authors.initials: Y
authors.lastname: Alsayed
authors.forename: Joshua
authors.initials: J
authors.lastname: Epstein
authors.forename: John
authors.initials: J
authors.lastname: Crowley
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D005500:Follow-Up Studies; D017353:Gene Deletion; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000069286:Bortezomib
references.citation: N Engl J Med. 2008 Aug 28;359(9):906-17
references.pmid: 18753647
references.citation: Genes Chromosomes Cancer. 1997 Jun;19(2):124-33
references.pmid: 9172003
references.citation: Blood. 2007 Mar 15;109(6):2276-84
references.pmid: 17105813
references.citation: Blood. 2003 Mar 15;101(6):2377-80
references.pmid: 12424198
references.citation: Cancer Res. 2004 Feb 15;64(4):1546-58
references.pmid: 14989251
references.citation: Br J Haematol. 2008 Mar;140(6):625-34
references.pmid: 18302711
references.citation: Blood. 2004 Jan 1;103(1):20-32
references.pmid: 12969978
references.citation: Leukemia. 2008 Dec;22(12):2247-56
references.pmid: 18769451
references.citation: Blood. 2006 Sep 15;108(6):2020-8
references.pmid: 16728703
references.citation: Cancer Res. 2007 Aug 1;67(15):7395-405
references.pmid: 17671210